Welcome to our dedicated page for Prophase Labs news (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on Prophase Labs stock.
ProPhase Labs, Inc. (PRPH) generates a steady flow of company news across biotech, genomics, and consumer health. Its press releases and regulatory disclosures cover developments in molecular diagnostics, whole genome sequencing, OTC dietary supplements, capital markets activity, and strategic initiatives. For investors and followers of PRPH, this news stream provides insight into how the company is advancing its programs and managing its capital structure.
A major news theme for ProPhase is the BE-Smart Esophageal Cancer Test. Company announcements describe peer-reviewed validation studies conducted with Mayo Clinic, publication in leading gastroenterology journals, and plans for commercialization and clinical integration. Updates often detail BE-Smart’s performance metrics, its role in Barrett’s Esophagus risk stratification, and steps toward broader adoption and reimbursement discussions.
Another recurring topic is genomics and Nebula Genomics. ProPhase’s news highlights its whole genome sequencing offerings and the positioning of Nebula Genomics as a consumer genomics platform with a large and diverse DNA dataset. Releases also discuss related consumer health initiatives, including DNA Complete and DNA Expand product lines, within the company’s genomics and wellness strategy.
Capital structure and financing updates are also prominent in PRPH news. Recent items include information on senior secured convertible notes and warrants registered via an S-1, an at-the-market sales agreement, a 1-for-10 reverse stock split to address listing requirements, and shareholder communications about trading activity, convertible debt conversions, and the transition from Nasdaq to the OTC market. These disclosures explain how ProPhase is addressing liquidity, managing dilution, and aligning its share structure with strategic goals.
Strategic and legal developments appear as well, such as a non-binding Letter of Intent for a proposed reverse merger with Advanced Biological Laboratories S.A., the Crown Medical Collections receivables recovery initiative, and updates on legal matters disclosed in Form 8-K filings. For readers tracking PRPH, this news page aggregates these diverse updates in one place, making it easier to follow the company’s diagnostics, genomics, consumer health, and corporate actions over time.
ProPhase Labs (NASDAQ:PRPH) has secured U.S. Patent No. 12379378-B2 for its biomarker-based systems and methods to assess progression risk in Barrett's esophagus and esophageal adenocarcinoma. The patent follows the successful validation of the company's BE-Smart™ molecular diagnostic test, which achieved a 95% technical success rate in detecting the patented biomarker panel.
The BE-Smart™ test platform demonstrates compatibility with both brush and forceps biopsies, enhancing early detection capabilities. The patent, filed in December 2023, covers methods for detecting key biomarkers including ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P, and GPI. The technology also enables novel treatment approaches and supports more accurate identification of high-risk patients.
ProPhase Labs (NASDAQ:PRPH), a biotech, genomics and consumer products company, has scheduled its second quarter 2025 financial results presentation for August 13, 2025, at 2:00 pm EDT. The company will host a virtual conference call through Renmark Financial, with financial results to be released via press release before the call.
Stakeholders and investors can attend the live event by registering through Renmark Financial's platform. A replay of the presentation will be made available on ProPhase's investor website after the event.
ProPhase Labs (NASDAQ: PRPH) has announced a Special Meeting of Shareholders scheduled for August 29, 2025, where shareholders will vote on increasing the company's authorized shares to 1 billion. The Board unanimously recommends voting 'FOR' all proposals.
The company aims to position itself for high-value structured transactions in the crypto treasury space, while simultaneously pursuing the collection of $50 million in Covid accounts receivables. ProPhase is also continuing the development of its BE-Smart™ esophageal cancer test and exploring strategic alternatives for Nebula Genomics, including a potential sale.
ProPhase Labs (NASDAQ: PRPH) has closed a $3 million private placement financing through senior secured convertible notes with accompanying warrants. The notes were issued with a 20% original issue discount and are secured by company assets. Key features include:
The warrants are exercisable at $0.50 per share, and the notes cannot be converted for the first four months. An additional $3 million in notes may be purchased by investors. The company plans to use proceeds for working capital, corporate purposes, and debt repayment.
CEO Ted Karkus indicated this financing serves as bridge capital while pursuing potential liquidity events, including collection of up to $50 million in Covid accounts receivable, potential sale of Nebula Genomics, and exploration of crypto treasury strategies.
ProPhase Labs (NASDAQ: PRPH) announced two major strategic initiatives: exploration of a potential reverse merger with a digital asset-focused company and approval of a cryptocurrency treasury initiative including Bitcoin investments. The Board unanimously authorized management to explore these opportunities while maintaining the company's existing business operations.
The company aims to maintain value from current initiatives including the Crown Medical Collections project (targeting up to $50 million in COVID accounts receivable), Nebula Genomics strategic alternatives, and the commercialization of the BE-Smart™ Esophageal cancer test. CEO Ted Karkus emphasized that this strategic move could create additional shareholder value while preserving existing assets.
ProPhase Labs (NASDAQ: PRPH) has received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement. The extension comes after the company failed to meet the requirement during the initial 180-day period ending June 24, 2025. ProPhase now has until December 22, 2025 to achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days to maintain its Nasdaq listing.
The extension was granted based on ProPhase meeting all other Capital Market initial listing requirements except the bid price requirement. If compliance is not achieved by the December deadline, Nasdaq will provide written notification of delisting. The company states this notice does not affect its business operations, SEC reporting requirements, or contractual obligations.
ProPhase Labs Inc. (NASDAQ: PRPH) has announced it will present its first quarter 2025 financial results in a virtual conference call on May 20, 2025, at 10:00 am EDT. The call, hosted by Renmark Financial, will feature CEO Ted Karkus providing updates on key initiatives, including:
- The planned sale of subsidiary Nebula Genomics
- Crown Medical Collections' initiative to recover tens of millions in accounts receivable
A press release with detailed results will be issued before the call. The company, a next-generation biotech, genomics and consumer products company, focuses on Whole Genome Sequencing solutions, diagnostic development including early esophageal cancer detection, and direct-to-consumer marketing for OTC dietary supplements.